Director

Ashoo Gupta

Vice President, Finance and Controller·4D Molecular Therapeutics, Inc.

About

Ashoo Gupta has served as 4DMT's Vice President, Finance & Controller since June 2024. He served as the Company's Principal Financial Officer and Principal Accounting Officer from September 30, 2025 until succeeded as Principal Accounting Officer by Kristian Humer on March 25, 2026; he signs the Company's 10-K as Principal Accounting Officer.

Prior to joining 4DMT, Mr. Gupta served as Vice President of Finance and Corporate Controller at Kyverna Therapeutics, Inc. from September 2023 to June 2024. From March 2019 to June 2023, he served as Executive Director of Accounting and Corporate Controller at Myovant Sciences, Inc.

Mr. Gupta holds a Bachelor of Commerce from the University of Mumbai and is a Certified Public Accountant.

Since 2024
Age 49
Tenure 2 yrs

Also at 4D Molecular Therapeutics, Inc.

DM David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director JP John F. Milligan, Ph.D. Director and Executive Chairman JM Jacob Chacko, M.D., MBA Director SM Susannah Gray, MBA Director CP Charles P. Theuer, M.D., Ph.D. Director NM Nancy Miller-Rich Director

Roles

Organization Role Dates Details
4D Molecular Therapeutics, Inc. Vice President, Finance and Controller 2024–present Current role
Kyverna Therapeutics, Inc. Vice President of Finance and Corporate Controller 2023-2024 VP of Finance and Corporate Controller from September 2023 to June 2024.
Myovant Sciences, Inc. Executive Director of Accounting and Corporate Controller 2019-2023 From March 2019 to June 2023.

Related

Source: 4D Molecular Therapeutics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo